Northland Capmk Forecasts Reduced Earnings for Alvotech

Alvotech (NASDAQ:ALVO) – Analysts at Northland Capmk cut their FY2025 earnings per share (EPS) estimates for Alvotech in a research note issued on Thursday, April 10th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.00 per share for the year, down from their previous forecast of $0.05. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share.

Alvotech (NASDAQ:ALVO) last released its earnings results on Wednesday, March 26th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.50. The business had revenue of $153.34 million for the quarter, compared to the consensus estimate of $97.99 million.

Separately, UBS Group assumed coverage on Alvotech in a report on Friday, February 14th. They issued a “buy” rating and a $18.00 price objective for the company.

Alvotech Trading Up 0.8 %

Shares of NASDAQ ALVO opened at $8.60 on Monday. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -4.65 and a beta of -0.05. The stock has a fifty day simple moving average of $10.82 and a two-hundred day simple moving average of $11.93. Alvotech has a 1-year low of $7.35 and a 1-year high of $14.76.

Institutional Trading of Alvotech

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new stake in shares of Alvotech in the fourth quarter worth about $66,000. GF Fund Management CO. LTD. purchased a new position in shares of Alvotech during the 4th quarter valued at $74,000. Wolverine Asset Management LLC raised its position in shares of Alvotech by 27.5% in the fourth quarter. Wolverine Asset Management LLC now owns 7,448 shares of the company’s stock worth $99,000 after buying an additional 1,607 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Alvotech in the 4th quarter valued at about $113,000. Finally, Invesco Ltd. purchased a new position in shares of Alvotech during the fourth quarter worth about $148,000.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.